Plasma Amyloid-beta Peptides, Depression and Alzheimer's Disease in the Homebound
Plasma Amyloid-beta Peptides, Depression and Alzheimer's Disease in the Homebound
批准号:
7646732
负责人:
WEI QIAO Wendy QIU
金额:
$41.76万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-15 至 2009-11-30
关键词:
AgeAlzheimer&aposs DiseaseAlzheimer&aposs disease riskAmyloidAmyloid beta-ProteinAntidepressive AgentsApolipoprotein EAreaBiological MarkersBiometryBloodBlood PlateletsBlood VesselsBostonBrainCardiovascular DiseasesCerebrospinal FluidCerebrumClinicClinicalCognitionCognitiveConfounding Factors (Epidemiology)CoupledCreatinineCross-Sectional StudiesDementiaDiagnosisDiseaseEarly treatmentEducationElderlyEpidemiologyEquilibriumEthnic OriginEvaluationGenderGeneral PopulationGenotypeGoalsImpaired cognitionIndividualLanguageLeadLinkLongitudinal StudiesManuscriptsMeasuresMemoryMorbidity - disease rateMusNeuraxisNeurobehavioral ManifestationsNeurologyNeuropsychologyNursing HomesOutcomePathologyPeptidesPeripheralPlasmaPopulationPrevalenceProductionProtein IsoformsProtein PrecursorsPsychiatryPublishingRecruitment ActivityRelative (related person)ResearchResearch PersonnelRiskRisk FactorsSamplingSeveritiesSourceSpinal PunctureStagingStrokeSubgroupTestingVisuospatialbasebrain metabolismcohortdepressiondisease diagnosisfollow-uphigh riskmortalitynovelprognosticprotein expressionpublic health relevanceresearch studytau Proteins
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Both Alzheimer?s disease (AD) and depression have become increasingly more prevalent in
the homebound elderly, leading to increased rates of morbidity, nursing home placement and
mortality, than what are found in the general elderly population. Our cross-sectional study of an
established homebound population in the Boston area has found that low plasma amyloid-a42
(Aa42) is associated with depression independently of cardiovascular disease. We further
found that depression with low Aa42 combined with high Aa42 in plasma is associated with
poor memory. Similarly other research studies have shown that a high plasma Aa40/Aa42
ratio significantly increased the risk of AD. Multiple studies demonstrate that plasma Aa
correlates with cerebral spinal fluid (CSF) Aa when cognition is normal, but this equilibrium
disappears after the AD cognitive symptoms occur. We hypothesize the existence of a
potential depression subtype associated with Ab peptides in plasma, which we have termed
?amyloid-associated depression?. The purpose of this R01 application is to validate the
existence of amyloid-associated depression defined by a high plasma Aa40/Aa42 ratio, and to
investigate whether this depression subtype is a prodromal depression of AD. The proposal is
based on our established population, and has two aims: Aim 1 is to document memory decline
prospectively in those with amyloid-associated depression vs. those with non-amyloid
depression vs. the controls. Aim 2 is to investigate the relationship between plasma Aa and
CSF Aa, a central nervous system (CNS) biomarker of AD, in the different depression
subgroups. Our long-term goal is to identify prodromal signs of AD to help facilitate early
treatment of the disease in the homebound elderly population.
PUBLIC HEALTH RELEVANCE: The proposed longitudinal study seeks to validate amyloid associated depression by investigating whether the combination of depression and a high plasma Aa40/Aa42 ratio will lead to greater risk of cognitive decline and the finding of the AD biomarkers in CSF as compared to those with a low plasma Aa40/Aa42 ratio or those without depression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterizing the interaction of genetic vulnerabilities and chronic peripheral inflammation for AD risk
-
批准号:10670352
-
项目类别:
-
资助金额:$49.89万
-
财政年份:2020
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Characterizing the interaction of genetic vulnerabilities and chronic peripheral inflammation for AD risk
-
批准号:10256774
-
项目类别:
-
资助金额:$38.59万
-
财政年份:2020
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Characterizing the interaction of genetic vulnerabilities and chronic peripheral inflammation for AD risk
-
批准号:10047359
-
项目类别:
-
资助金额:$40.08万
-
财政年份:2020
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Characterizing the interaction of genetic vulnerabilities and chronic peripheral inflammation for AD risk
-
批准号:10468285
-
项目类别:
-
资助金额:$50.64万
-
财政年份:2020
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Midcareer Investigator Award in Amylin, Cognition, and Alzheimer's Disease
-
批准号:9298592
-
项目类别:
-
资助金额:$17.03万
-
财政年份:2015
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Removal of Amyloid-beta Peptides from the Alzheimer's Brain
-
批准号:8718074
-
项目类别:
-
资助金额:$17.24万
-
财政年份:2014
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Amylin as a Diagnostic Test and Potential Treatment for Alzheimers Disease
-
批准号:8694671
-
项目类别:
-
资助金额:$24.56万
-
财政年份:2014
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Plasma Amyloid-beta Peptides, Depression and Alzheimer's Disease in the Homebound
-
批准号:8096676
-
项目类别:
-
资助金额:$40.15万
-
财政年份:2009
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Plasma Amyloid-beta Peptides, Depression and Alzheimer's Disease in the Homebound
-
批准号:8464619
-
项目类别:
-
资助金额:$32.87万
-
财政年份:2009
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Amyloid-beta Peptides, Depression and Alzheimer's Disease
-
批准号:8284382
-
项目类别:
-
资助金额:$40.05万
-
财政年份:2009
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Plasma Amyloid-beta Peptides, Depression and Alzheimer's Disease in the Homebound
-
批准号:7883340
-
项目类别:
-
资助金额:$40.67万
-
财政年份:2009
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Insulin, Cognitive Impairment and Alzheimer's Disease
-
批准号:6676098
-
项目类别:
-
资助金额:$12.87万
-
财政年份:2003
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Insulin, Cognitive Impairment and Alzheimer's Disease
-
批准号:6803009
-
项目类别:
-
资助金额:$12.86万
-
财政年份:2003
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Insulin, Cognitive Impairment and Alzheimer's Disease
-
批准号:7103613
-
项目类别:
-
资助金额:$13.38万
-
财政年份:2003
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Insulin, Cognitive Impairment and Alzheimer's Disease
-
批准号:6934520
-
项目类别:
-
资助金额:$13.32万
-
财政年份:2003
-
负责人:WEI QIAO Wendy QIU
-
依托单位:
Insulin, Cognitive Impairment and Alzheimer's Disease
-
批准号:7270602
-
项目类别:
-
资助金额:$13.38万
-
财政年份:2003
-
负责人:WEI QIAO Wendy QIU
-
依托单位: